Lilly 

4Q Revenues: $19.3 billion +43%

4Q Earnings: $6.6 billion +50%

FY Revenues: $65.2 billion +45% 

FY Earnings: $20.6 billion +95%

Comments: Growth in the quarter driven by a 46% increase in volume, partially offset by a 5% decrease due to lower realized prices. Key Products revenue grew to $13.8 billion in the quarter, led by Mounjaro and Zepbound. 

Mounjaro sales were $7.4 billion in the quarter, up 110%. Zepbound sales were $4.3 billion, up 123%. Verzenio sales were $1.6 billion, up 3%. Other Key Products include Ebglyss, Inluriyo, Jaypirca, Kisunla, Omvoh.

Talz sales were $1.1 billion in the quarter, up 10%. Trulicity sales were down 17% to $1.0 billion.